Pfizer to acquire Arena Pharmaceuticals

By The Science Advisory Board staff writers

December 14, 2021 -- Pfizer will acquire all outstanding shares of Arena Pharmaceuticals for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion.

Arena's portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases, including gastrointestinal and dermatological diseases.

Arena has built a robust development program for etrasimod, including two phase III studies in ulcerative colitis (UC), a phase II/III program in Crohn's disease, a planned phase III program in atopic dermatitis, and ongoing phase II studies in eosinophilic esophagitis and alopecia areata. The data for the phase II OASIS trial for UC are expected to be reported in 2022.

Pfizer's financial advisors for the acquisition were Bank of America Securities and Centerview Partners while Ropes and Gray and Arnold and Porter Kaye Scholer acted as legal advisors. Guggenheim Securities and Evercore Group served as Arena's financial advisors, and Cooley served as its legal advisor.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here